000597 Stock Overview
Engages in the chemical raw materials, chemical preparations, pharmaceutical, pharmaceutical engineering, biomedicine, and other businesses in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
Northeast Pharmaceutical Group Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥5.58 |
| 52 Week High | CN¥6.69 |
| 52 Week Low | CN¥3.72 |
| Beta | 0.25 |
| 1 Month Change | 7.31% |
| 3 Month Change | 22.10% |
| 1 Year Change | 4.89% |
| 3 Year Change | -1.24% |
| 5 Year Change | 8.12% |
| Change since IPO | 23.14% |
Recent News & Updates
Recent updates
Shareholder Returns
| 000597 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 2.8% | -2.3% | -0.5% |
| 1Y | 4.9% | -5.4% | 9.2% |
Return vs Industry: 000597 exceeded the CN Pharmaceuticals industry which returned -4.3% over the past year.
Return vs Market: 000597 underperformed the CN Market which returned 10.8% over the past year.
Price Volatility
| 000597 volatility | |
|---|---|
| 000597 Average Weekly Movement | 7.2% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 13.0% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 000597 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 000597's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1946 | 6,214 | Zhou Kai | www.nepharm.com.cn |
Northeast Pharmaceutical Group Co., Ltd. engages in the chemical raw materials, chemical preparations, pharmaceutical, pharmaceutical engineering, biomedicine, and other businesses in China. It offers vitamin products, including vitamin C, vitamin B1, vitamin B6, and levocarnitine series; anti-infection products, such as fosfomycin series, azithromycin series, berberine hydrochloride, chloramphenicol, and other products.; and reproductive system and sex hormone products comprising carprost, carboprost tromethamine, dapoxetine hydrochloride, and levonorgestrel and tadalafil tablets. The company also provides nervous system products, such as piracetam series, levetiracetam series, vinpocetine, and other products; essence and cannabis-containing series products, including morphine hydrochloride injection, pethidine hydrochloride injection, compound codeine phosphate syrup, morphine hydrochloride tablets, and oxycodone hydrochloride injection; anti-AIDS products comprising kedu/zidovudine tablets, efavirenz tablets, and other products; digestive system products, which include bacillus licheniformis, aluminum magnesium carbonate chewable tablets, and other products; and in vitro biological diagnostic reagent products, such as HIV, HBV, HCV, HPV, and TB molecular diagnostic reagents.
Northeast Pharmaceutical Group Co., Ltd. Fundamentals Summary
| 000597 fundamental statistics | |
|---|---|
| Market cap | CN¥7.97b |
| Earnings (TTM) | CN¥346.65m |
| Revenue (TTM) | CN¥7.97b |
23.0x
P/E Ratio1.0x
P/S RatioIs 000597 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 000597 income statement (TTM) | |
|---|---|
| Revenue | CN¥7.97b |
| Cost of Revenue | CN¥5.36b |
| Gross Profit | CN¥2.61b |
| Other Expenses | CN¥2.27b |
| Earnings | CN¥346.65m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.24 |
| Gross Margin | 32.80% |
| Net Profit Margin | 4.35% |
| Debt/Equity Ratio | 39.7% |
How did 000597 perform over the long term?
See historical performance and comparisonDividends
1.8%
Current Dividend Yield41%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 12:02 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Northeast Pharmaceutical Group Co., Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jie Yao | Citic Securities Co., Ltd. |
| Xiaoming Liu | Guoyuan Securities Co., Ltd. |
| Yining Zheng | Topsperity Securities |